StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Analysts at StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a note issued to investors on Monday. The firm set a “hold” rating on the stock.

Tonix Pharmaceuticals Price Performance

Shares of Tonix Pharmaceuticals stock opened at $0.61 on Monday. The stock has a market capitalization of $114.30 million, a P/E ratio of -0.01 and a beta of 2.23. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $14.08. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The business’s 50 day simple moving average is $0.20 and its two-hundred day simple moving average is $0.46.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Analysts forecast that Tonix Pharmaceuticals will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.